Navigation Links
FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
Date:8/30/2007

SUNNYVALE, Calif., Aug. 30 /PRNewswire/ -- Conformia, one of the FDA's Cooperative Research and Development Agreement (CRADA) Partners, joined forces with the Food and Drug Administration (FDA) on August 23, 2007, in a presentation focusing on the FDA's Quality by Design (QbD) initiative at the Third Annual Regulatory and Compliance Symposium -- "Managing Risks -- From Pipeline to Patient." The symposium was held at Harvard University.

Helen Winkle, Director of the Office of Pharmaceutical Sciences, a part of the Center for Drug Evaluation and Research, shared the progress the FDA is making, as well as the challenges that both the FDA and the industry face in moving to the "desired state." Winkle pointed out that Chemistry Manufacturing and Controls (CMC) requirements are part of the critical path both within the FDA and within industry, and described how the Quality by Design (QbD) initiative is created to help reduce excessive regulatory burden and provide mechanisms for regulatory flexibility.

Anjali Kataria, principal investigator of the FDA-Conformia Cooperative Research and Development Agreement (CRADA) study, presented research from the CRADA study of nine blinded pharmaceutical / biotech companies. She highlighted results including the bottlenecks and obstacles companies face in implementing QbD, as well as the top priorities study companies articulated -- such as gaining more assurance from the FDA that reviewers, inspectors and policy makers are all being trained to support the "desired state."

Winkle and Kataria presented both findings and actions resulting from part one of the Conformia CRADA study that queried pharmaceutical and biotech leaders about meeting the goals of the FDA's QbD initiative. The preliminary findings led to an expanded CRADA study and a series of first-of-a-kind Conformia-FDA-PhRMA trainings for cross-functional pharmaceutical leadership teams.

The Harvard presentation focused on:

-- The state of pharmaceutical manufacturing

-- Consequences pharmaceutical companies face in the present environment

-- The current state of the regulatory quality review process

-- The mutual goal for industry, society and regulators to reliably

produce high-quality products without extensive regulatory oversight

-- Benefits of the new QbD paradigm for both the FDA and the industry

About the CRADA Study

The CRADA study began in April 2006 as a preliminary study of nine companies and is due to expand to 25 companies. Focusing on understanding the current practices of pharmaceutical development and commercialization, the study is designed to align with the FDA's Current Good Manufacturing Practice (cGMP) initiative for the 21st century and the Critical Path initiative, of which QbD is a key component. The study is unique because it enables companies to openly share their concerns with the FDA without fear of ramifications.

The presentation is available on the Conformia website -- http://www.conformia.com

About Conformia

Conformia is the market leader and innovator in product/process lifecycle management (PPLM) software solutions for regulated process industries including life sciences and beverage alcohol. These solutions enable pharmaceutical companies to save significant time and money through major improvements in product/process development operations by creating central master active pharmaceutical ingredients and formulation databases across the lifecycle. Conformia's web-based enterprise software helps improve product quality, provides a platform for regulatory flexibility, decreases time to market, increases product / process operational effectiveness and streamlines tech transfer. Conformia is offered as an SAP-endorsed business solution for pharmaceutical development operations and beverage alcohol operations. Together SAP and Conformia are building a bridge to support the product/process lifecycle from development to manufacturing thereby enabling companies to achieve Quality by Design across the lifecycle. For more information, go to http://www.conformia.com.

Conformia is a registered trademark of Conformia Software Inc. All other brands, products, or service names are or may be trademarks or service marks of their respective owners.


'/>"/>
SOURCE Conformia
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
2. High-Titer Retroviral Vectors for Gene Delivery
3. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
4. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
5. A New Way to Assess siRNA Delivery Efficiency
6. Delivering siRNA Using Adenoviral Vectors
7. Efficient Delivery of siRNAs to Human Primary Cells: Electroporation vs. Chemical Transfection
8. Delivering siRNAs to Difficult Cell Types
9. Enhanced siRNA Delivery and Long-term Gene Silencing
10. Deliver siRNAs Into Primary Cells
11. High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... New FDA action date of July 22, 2016 ... 22, 2016   --> - New ... - Lifitegrast has the potential to be the only product ... signs and symptoms of dry eye disease in adults --> ... in the U.S. in the past decade indicated for the treatment of signs ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):